Acta Clinica Croatica (Jan 2022)

Impact of Graves’ Disease and Antithyroid Drug Therapy on Bone Mineral Density – Pathophysiological Mechanisms and Clinical Relevance

  • Dunja Mudri,
  • Tomislav Kizivat,
  • Martina Smolić,
  • Ivica Mihaljević,
  • Robert Smolić,
  • Nikola Raguž Lučić,
  • Ines Bilić-Ćurčić

DOI
https://doi.org/10.20471/acc.2022.61.03.15
Journal volume & issue
Vol. 61., no. 3
pp. 496 – 504

Abstract

Read online

Graves’ disease is an autoimmune disease characterized by excessive thyroid hormone production. One of the consequences of that state can be a decrease in bone mineral density (BMD). Graves’ disease is often treated with antithyroid drugs (ATD) as first line therapy, which can lead to disease remission. Moreover, recent data show that improvement in BMD can be expected. However, vitamin D deficiency can coexist along with Graves’ disease, which is also involved in the process of bone remodeling. It is still not known whether lower values of vitamin D can contribute to onset of Graves’ disease and if its supplementation might be helpful in therapy for hyperthyroidism. In the past couple of decades, osteopenia and osteoporosis have become a major health burden not only in post-menopausal women but also as a result of other diseases, leading to extensive research into various pathophysiological mechanisms responsible for bone remodeling. The Wnt (wingless integrated) signaling pathway is a very important factor in bone homeostasis, especially the canonical pathway. Present data indicate that stimulation of the Wnt pathway leads to bone mass increase and, in contrast, its inhibition leads to bone mass decrease. Hence, inhibitors of the canonical Wnt pathway became the focus of interest, in particular sclerostin and dickkopf 1 (DKK1). Hyperthyroidism and osteopenia/osteoporosis are quite common today and can coexist together or as separate entities. In this article, we aimed to give an overview of possible associations and potential mutual pathophysiological mechanisms.

Keywords